33424664|t|Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.
33424664|a|Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. While there continues to be expansive research in posttraumatic stress disorder (PTSD), depression and schizophrenia, there is a relative dearth of novel medications under investigation for anxiety disorders. This review's first aim is to summarize current pharmacological treatments (both approved and off-label) for panic disorder (PD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and specific phobias (SP), including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), azapirones (e.g., buspirone), mixed antidepressants (e.g., mirtazapine), antipsychotics, antihistamines (e.g., hydroxyzine), alpha- and beta-adrenergic medications (e.g., propranolol, clonidine), and GABAergic medications (benzodiazepines, pregabalin, and gabapentin). Posttraumatic stress disorder and obsessive-compulsive disorder are excluded from this review. Second, we will review novel pharmacotherapeutic agents under investigation for the treatment of anxiety disorders in adults. The pathways and neurotransmitters reviewed include serotonergic agents, glutamate modulators, GABAergic medications, neuropeptides, neurosteroids, alpha- and beta-adrenergic agents, cannabinoids, and natural remedies. The outcome of the review reveals a lack of randomized double-blind placebo- controlled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents. Although there are some recent randomized controlled trials for novel agents including neuropeptides, glutamatergic agents (such as ketamine and d-cycloserine), and cannabinoids (including cannabidiol) primarily in GAD or SAD, these trials have largely been negative, with only some promise for kava and PH94B (an inhaled neurosteroid). Overall, the progression of current and future psychopharmacology research in anxiety disorders suggests that there needs to be further expansion in research of these novel pathways and larger-scale studies of promising agents with positive results from smaller trials.
33424664	19	36	Anxiety Disorders	Disease	MESH:D001008
33424664	78	95	Anxiety disorders	Disease	MESH:D001008
33424664	119	140	psychiatric disorders	Disease	MESH:D001523
33424664	226	255	posttraumatic stress disorder	Disease	MESH:D013313
33424664	257	261	PTSD	Disease	MESH:D013313
33424664	264	274	depression	Disease	MESH:D003866
33424664	279	292	schizophrenia	Disease	MESH:D012559
33424664	366	383	anxiety disorders	Disease	MESH:D001008
33424664	494	508	panic disorder	Disease	MESH:D016584
33424664	510	512	PD	Disease	MESH:D016584
33424664	515	543	generalized anxiety disorder	Disease	MESH:C000726808
33424664	545	548	GAD	Disease	MESH:C000726808
33424664	551	574	social anxiety disorder	Disease	MESH:D000072861
33424664	576	579	SAD	Disease	MESH:D000072861
33424664	586	602	specific phobias	Disease	MESH:C562465
33424664	604	606	SP	Disease	MESH:C562465
33424664	668	712	serotonin norepinephrine reuptake inhibitors	Chemical	-
33424664	714	719	SNRIs	Chemical	-
33424664	722	732	azapirones	Chemical	-
33424664	740	749	buspirone	Chemical	MESH:D002065
33424664	781	792	mirtazapine	Chemical	MESH:D000078785
33424664	833	844	hydroxyzine	Chemical	MESH:D006919
33424664	847	885	alpha- and beta-adrenergic medications	Chemical	-
33424664	893	904	propranolol	Chemical	MESH:D011433
33424664	906	915	clonidine	Chemical	MESH:D003000
33424664	922	943	GABAergic medications	Chemical	-
33424664	945	960	benzodiazepines	Chemical	MESH:D001569
33424664	962	972	pregabalin	Chemical	MESH:D000069583
33424664	978	988	gabapentin	Chemical	MESH:D000077206
33424664	991	1020	Posttraumatic stress disorder	Disease	MESH:D013313
33424664	1025	1054	obsessive-compulsive disorder	Disease	MESH:D009771
33424664	1183	1200	anxiety disorders	Disease	MESH:D001008
33424664	1285	1294	glutamate	Chemical	MESH:D018698
33424664	1307	1328	GABAergic medications	Chemical	-
33424664	1360	1393	alpha- and beta-adrenergic agents	Chemical	-
33424664	1395	1407	cannabinoids	Chemical	MESH:D002186
33424664	1530	1547	anxiety disorders	Disease	MESH:D001008
33424664	1754	1762	ketamine	Chemical	-
33424664	1767	1780	d-cycloserine	Chemical	MESH:D003523
33424664	1787	1799	cannabinoids	Chemical	MESH:D002186
33424664	1811	1822	cannabidiol	Chemical	MESH:D002185
33424664	1837	1840	GAD	Disease	MESH:C000726808
33424664	1844	1847	SAD	Disease	MESH:D000072861
33424664	1926	1931	PH94B	Chemical	-
33424664	2037	2054	anxiety disorders	Disease	MESH:D001008
33424664	Negative_Correlation	MESH:D002065	MESH:C562465
33424664	Negative_Correlation	MESH:D002185	MESH:C000726808
33424664	Negative_Correlation	MESH:D002185	MESH:D000072861
33424664	Negative_Correlation	MESH:D001569	MESH:D001008
33424664	Negative_Correlation	MESH:D003523	MESH:C000726808
33424664	Negative_Correlation	MESH:D002186	MESH:D000072861
33424664	Negative_Correlation	MESH:D003523	MESH:D000072861
33424664	Negative_Correlation	MESH:D002186	MESH:C000726808

